Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Drug for treating coronary heart disease and preparation process

A coronary heart disease and drug technology, applied in the field of drugs for the treatment of coronary heart disease, can solve the problems of low content of active ingredients, no quality control indicators, backward production technology, etc.

Active Publication Date: 2011-04-27
TIANJIN TASLY MORDEN TCM RESOURCES
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are ordinary compound Danshen tablets and capsules on the market, but the production technology of ordinary tablets and capsules is backward, the content of active ingredients is low, and there is no quality control index. It needs to be taken orally and absorbed through the gastrointestinal tract, and absorbed after the first-pass effect in the liver. Into the blood, low bioavailability, slow absorption. It is not suitable for the first aid needs of patients with angina pectoris

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for treating coronary heart disease and preparation process
  • Drug for treating coronary heart disease and preparation process
  • Drug for treating coronary heart disease and preparation process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] For the preparation of the medicine for treating coronary heart disease, the weight percentages of the active ingredients of the medicine are as follows: Danshen 82.87%, Panax notoginseng 16.21%, and Borneol 0.92%;

[0074] Step 1: Extract 5 times the amount of Danshen with 95% ethanol under reflux for 2 hours, filter, use 3 times the amount of 95% ethanol for the dregs, extract under reflux for 1 hour, filter, use the dregs to extract salvianolic acid B, and concentrate the filtrate to 0.4- 0.5 times the amount of medicinal materials, let it stand, and filter; precipitate and dry to obtain the first part of Tanshinone II A extract; apply AB-8 macroporous resin to the filtrate, elute with 70% ethanol, discard the eluent, and continue to elute with 95% ethanol , collect the eluent, concentrate to 80% alcohol content, let stand, filter, and dry the precipitate under reduced pressure to obtain the second part of Tanshinone II A extract, and combine the two parts to obtain T...

Embodiment 2

[0079] Embodiment 2 The preparation of the medicine for treating coronary heart disease, each component is composed of the weight percentage of the active ingredients of the medicine based on the crude drug: 19.8% of Danshen, 78.2% of Radix Notoginseng, and 2% of Borneolum;

[0080] Step 1: Extract 2 times the amount of Danshen with 95% ethanol under reflux for 1 hour, filter, use 20 times the amount of 95% ethanol for the dregs, extract under reflux for 1 hour, filter, use the dregs to extract salvianolic acid B, and concentrate the filtrate to 0.4- 0.6 times the amount of medicinal materials, let it stand, and filter; precipitate and dry to obtain the first part of Tanshinone IIA extract; apply AB-8 macroporous resin to the filtrate, elute with 70% ethanol, discard the eluent, continue to elute with 95% ethanol, Collect the eluate, concentrate to 80% alcohol content, let it stand, filter, and dry the precipitate under reduced pressure to obtain the second part of Tanshinone I...

Embodiment 3

[0085] The preparation of embodiment 3 compound danshen dripping pills, each component is composed of the weight percent of active ingredient of medicine based on crude drug: 97% of salvia miltiorrhiza, 2% of notoginseng, 1% of borneol,

[0086] Step 1: Extract 2 times the amount of Danshen with 95% ethanol under reflux for 1 hour, filter, use 20 times the amount of 95% ethanol for the dregs, extract under reflux for 10 hours, filter, use the dregs to extract salvianolic acid B, and concentrate the filtrate to 0.2 times Amount of medicinal material, let it stand, and filter; precipitate and dry to obtain the first part of Tanshinone II A extract; apply AB-8 macroporous resin to the filtrate, elute with 50% ethanol, discard the eluent, continue to elute with 85% ethanol, and collect Concentrate the eluent to an alcohol content of 65%, let it stand, filter, and dry the precipitate under reduced pressure to obtain the second part of the tanshinone IIA extract, and combine the two ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug for treating coronary heart disease and a preparation process. The preparation method comprises the following steps: extracting salvia and notoginseng with alcohol, extracting dregs of salvia with alcohol and the like. The invention has the following advantages: the process route can realize industrialization and the quality is stable and controllable. Relevant experiments show that the drug has the advantages of high curative effect and product purity, good absorbability, stable quality and novel application compared with the prior art, and meanwhile, the preparation method is simple in process, convenient to operate, low in cost and suitable for industrial production.

Description

technical field [0001] The invention relates to a medicine for treating coronary heart disease, which belongs to the field of traditional Chinese medicine. Background technique [0002] With the improvement of living standards, the aging of the world's population and the rejuvenation of the disease population, cardiovascular and cerebrovascular patients are increasing year by year, and have become the second largest disease that endangers human health. Angina pectoris is a clinical syndrome caused by temporary myocardial ischemia and hypoxia, with episodic chest pain or chest discomfort as the main manifestation. Coronary heart disease angina pectoris refers to angina pectoris caused by myocardial ischemia and hypoxia due to coronary artery sclerosis or spasm, accounting for about 90% of angina pectoris patients. [0003] The current methods of treating angina pectoris mainly focus on dilating blood vessels, reducing blood viscosity, anti-platelet aggregation, and anti-coag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/537A61K9/20A61P9/10A61K31/045
Inventor 刘顺航徐波戚可人刘岩陈红丛德刚赵国辉
Owner TIANJIN TASLY MORDEN TCM RESOURCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com